Roscovitine
Roscovitine is an inhibitor of CDKs (1, 2, 5, 7, 9, 12) and L-type Ca2+ channels; it exhibits anti-inflammatory and anticancer activities. Roscovitine resolves neutrophil-driven inflammation. In B-cell lymphoma cells, roscovitine induces cell cycle arrest and apoptosis and inhibits proliferation.
References PubMed ID：:http://www.ncbi.nlm.nih.gov/pubmed/18964862
| Cas No. |
186692-46-6 |
|---|---|
| Purity |
≥98% |
| Formula |
C19H26N6O |
| Formula Wt. |
354.45 |
| Chemical Name |
2-(R)-(1-Ethyl-2-hydroxyethylamino)-6-benzylamino- 9-isopropylpurine |
| IUPAC Name |
DISCONTINUED |
| Synonym |
Seliciclib, CYC202 |
| Melting Point |
106-109°C |
| Solubility |
Soluble in DMSO or chloroform. |
| Appearance |
White crystalline solid |
Leitch AE, Haslett C, Rossi AG. Cyclin-dependent kinase inhibitor drugs as potential novel anti-inflammatory and pro-resolution agents. Br J Pharmacol. 2009 Oct;158(4):1004-16. PMID: 19775281.
Yarotskyy V, Elmslie KS. Roscovitine, a cyclin-dependent kinase inhibitor, affects several gating mechanisms to inhibit cardiac L-type (Ca(V)1.2) calcium channels. Br J Pharmacol. 2007 Oct;152(3):386-95. PMID: 17700718.
Lacrima K, Rinaldi A, Vignati S, et al. Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas. Leuk Lymphoma. 2007 Jan;48(1):158-67. PMID: 17325859.
